Use of trifluoroacetic acid to quantify small, polar compounds in rat plasma during discovery-phase pharmacokinetic evaluation

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Sep 1;856(1-2):165-70. doi: 10.1016/j.jchromb.2007.05.024. Epub 2007 Jun 2.

Abstract

Although it is accepted that trifluoroacetic acid (TFA) can cause suppression of an analyte during LC/MS analysis, this paper presents a relatively sensitive gradient method that uses a TFA mobile phase for the improved quantification of small, polar drug-like compounds. The described method was developed in a discovery drug metabolism and pharmacokinetics (DMPK) laboratory for the screening measurement of compound concentrations to calculate PK parameters and CNS exposure of compounds from a chemical series that had poor chromatography under generic methods using formic acid mobile phase. The samples were collected by a Culex automated sampling unit, and the plasma proteins were precipitated by a Tecan robot in 96-well plates. After centrifugation, the supernatant was removed, dried down using a SPE-Dry unit, and the samples were reconstituted in aqueous buffer on the robot. The samples were analyzed on an Agilent LC/MSD using a 5-min gradient on a 5 cm phenyl column. No additional steps, such as the "TFA-fix", were necessary. Although sample batches were analyzed over 6h, no drift or degradation of signal was observed. The improved chromatography resulted in a method that was selective, rugged, and had a dynamic range from 5 to 20,000 nM, which was sufficient to quantitate low volume, serial plasma samples collected out to 8 h postdose.

MeSH terms

  • Animals
  • Calibration
  • Chromatography, High Pressure Liquid
  • Humans
  • Pharmaceutical Preparations / blood*
  • Pharmacokinetics*
  • Rats
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Trifluoroacetic Acid / chemistry*

Substances

  • Pharmaceutical Preparations
  • Trifluoroacetic Acid